QPS

QPS Delaware expands translational medicine capabilities

Wednesday, August 9, 2017

QPS Holdings, a full-service GLP/GCP-compliant CRO providing testing services to support preclinical and clinical research and development, is investing in additional technical personnel and laboratory capacity for translational medicine at its flagship Delaware Technology Park facility. This significant expansion will enable QPS Delaware to process the high sample volumes required for phase III clinical drug trials.

[Read More]

QPS opens in vitro dermal, transdermal research laboratory in North Dakota

Thursday, May 14, 2015

QPS Holdings, a full-service CRO, has opened a new in vitro dermatology and transdermal research laboratory in Fargo, N.D. This new physical extension of QPS’ dermal and transdermal research services portfolio will further strengthen QPS’ ability to assist clients in quickly moving their dermal and transdermal products from preclinical evaluations through to late stage clinical development.

[Read More]

QPS Holdings, Hepregen partner

Monday, June 3, 2013

QPS Holdings, a U.S.-based CRO, and Hepregen, developer of HepatoPac and HepatoMune “liver-in-a-dish” products, have partnered to provide QPS a license to offer drug metabolism and pharmacokinetic (DMPK) services to its clients using Hepregen’s products, in both the U.S. and Europe. The partnership also includes marketing and sales, providing co-promotion of the HepatoPac-associated DMPK services. This arrangement is the first such partnership in the field for both companies.

[Read More]

CRO QPS acquires Qualitix

Wednesday, March 9, 2011

QPS, a global GLP/GCP-compliant CRO providing testing services for preclinical and clinical R&D, has acquired a majority interest of Qualitix Clinical Research. Qualitix, a spin-off of Taiwan-based biotech Genovate, is a CRO and site management organization (SMO) with offices in Taiwan and China. Genovate will retain a minority interest in Qualitix, which will be known as QPS-Qualitix Taiwan.

[Read More]

ICON, QPS Receive Industry Accreditations

Friday, September 18, 2009

Dublin, Ireland-based contract research organization (CRO) ICON received industry accreditations for three of its laboratories in the UK and Singapore, and Newark, Del.-based QPS received a Good Laboratory Practice (GLP) certificate for its Taiwan operations.

[Read More]

QPS Bolsters New Translational Medicine Group

Wednesday, August 6, 2008

Newark, Del.-based QPS, a provider of research services for the pharmaceutical industry, named Dr. LingSing K. Chen to head its new Translational Medicine department.

“In its Critical Path Initiative, the FDA identified—correctly, we believe—the need for this country to make significant improvements to the process under which new drugs are developed,” said Dr. Ben Chien, QPS president and chief executive officer. “By adding a department of Translational Medicine, we hope to play an integral role in the process of moving research discoveries from the laboratory into clinical practice more rapidly.”

Translational medicine is a scientific discipline that refers to the translation of basic research into new therapies for patients.

“The remarkable growth in our biomarkers business areas led us to consider this path,” Dr. Chien said. “QPS considers the creation of a Translational Medicine department pivotal to providing new technologies to support preclinical and clinical drug development worldwide.”

Chien noted that many QPS clients have already formed Translational Medicine units to facilitate the interaction between basic research and clinical medicine, particularly in clinical trials.

Chien said QPS would combine two existing groups, Immunobiomarker and Molecular Biology, to form the new department. Dr. LingSing K. Chen, former executive director of the Molecular Biology group, will head QPS’ new Translational Medicine department.

“Dr. Chen is a founding member of our Molecular Biology group and has established very diverse capabilities within a short period of time,” Chien said. “She is a determined leader with a great deal of entrepreneurial spirit and I have every reason to believe in the success of our new venture.”

Prior to joining QPS, Chen held executive positions at Wyeth Pharmaceuticals and as a senior advisor to the Industrial Technology Research Institute (ITRI) in Taiwan.

[Read More]